FDA advisers vote to support Paxlovid for COVID-19 treatment in high-risk adults

Mar 18, 2023, 1:06 PM | Updated: Mar 22, 2023, 7:33 am


PEMBROKE PINES, FLORIDA - JULY 07: In this photo illustration, Pfizer's Paxlovid is displayed on July 07, 2022 in Pembroke Pines, Florida. The US Food and Drug Administration revised the emergency use authorization for Paxlovid, Pfizer's Covid-19 antiviral treatment, to allow state-licensed pharmacists to prescribe the treatment to people. (Photo by Joe Raedle/Getty Images)

(Photo by Joe Raedle/Getty Images)

Originally Published: 16 MAR 23 06:35 ET
Updated: 17 MAR 23 11:01 ET

(CNN) — Advisers to the US Food and Drug Administration voted 16-1 on Thursday in support of full approval of Paxlovid, stating that the benefits outweigh the risks of the drug for treatment of mild to moderate Covid-19 in adults who are at high risk for severe disease, including hospitalization and death.

Before the antiviral medication is fully approved, the FDA — which typically follows the recommendations of its independent advisory committee — must conduct its own review. That’s expected to wrap up in May.

More than 8 million people in the US have received Paxlovid, a combination of the drugs nirmatrelvir and ritonavir, since it became available under emergency use authorization in December 2021.

“I’d say besides oxygen, Paxlovid has probably been the single most important tool in this epidemic, and it continues to be,” said Dr. Richard Murphy, chief of infectious diseases with the Veterans Affairs White River Junction Medical Center and a member of the FDA’s Antimicrobial Drugs Advisory Committee, who voted in support of approval at the meeting.

“We still have many groups that stand to benefit from the use of Paxlovid, including unvaccinated persons, undervaccinated persons, elderly, immunocompromised, and the other treatment options that we have have significant disadvantages,” he said.

A study published Friday in the medical journal JAMA Health Forum estimated that if Paxlovid uptake during the winter Omicron wave had been what it is now, nearly 5,000 deaths would have been prevented.

Data from phase 2 and 3 clinical trials supports the efficacy of Paxlovid regardless of Covid vaccination status or prior infection, the FDA said in documents released ahead of Thursday’s meeting. The agency also said it is reasonable to conclude, despite limited data, that Paxlovid is “likely to retain clinical efficacy” in high-risk adults with Covid infection caused by the Omicron variant of the coronavirus, as with earlier variants.

“I thought that the efficacy data were clear and convincing,” said Dr. Shankar Swaminathan, chief of infectious diseases at the University of Utah School of Medicine, who voted in support of approval Thursday. “I think that the fact that the drug has retained activity against various evolutionary strains of the virus is also reassuring and gives hope that this will continue to be the case going forward.”

Not linked to COVID-19 rebound

The FDA also concluded that Paxlovid is not associated with Covid-19 rebound, in which people test positive or see their symptoms return after they finish the five-day course of the drug.

The agency said it has reviewed data regarding rebound cases, which some users have reported since Paxlovid was authorized in 2021. Last year, both President Joe Biden and his former chief medical adviser, Dr. Anthony Fauci, reported rebound symptoms after taking Paxlovid.

However, based on clinical trial data, the FDA “did not identify a clear association between Paxlovid treatment and Covid-19 rebound.”

Covid rebound rates ranged from 10% to 16%, with no difference between people who took Paxlovid and those who took a placebo. This was also regardless of a person’s risk of severe disease with the Omicron variant compared with the Delta variant, according to clinical trial data reviewed by the FDA.

Overall, the agency said, the findings indicate that Covid-19 rebound may occur in a subset of infections as part of the natural progression and resolution of the disease.

Monitoring drug-drug interactions

No major safety concerns were identified in the clinical trial data, the FDA said. However, the agency has flagged 137 medications with Paxlovid drug-drug interactions (DDIs) that may lead to serious adverse reactions.

Paxlovid may keep the body from metabolizing certain drugs, leading to higher drug concentrations that can lead to serious or life-threatening reactions, according to an FDA Emergency Use Authorization Fact Sheet. Drugs that should not be taken with Paxlovid include some medications to treat conditions such as high cholesterol, gout, migraine, irregular heartbeat and benign prostatic hyperplasia.

According to the agency, more than 50% of Paxlovid-eligible patients may be on medication with a DDI at the time of Covid diagnosis.

“I would just emphasize that we underscore the importance of risk-mitigation to the prescriber, primary care physicians and other prescribers in terms of drug-drug interactions,” said FDA committee member Dr. David Hardy, an adjunct clinical professor at the Keck School of Medicine at the University of Southern California, who voted in support of approval. “That’s where I think we may get into trouble — or I can say where they can get into trouble — prescribing this medication without a good knowledge of what ritonavir does to other medications.”

The committee said the benefits of Paxlovid may not outweigh the risk of adverse drug reactions in all patients. For those at high risk of severe Covid-19, DDIs can be managed by holding the drug, adjusting the dose or increasing monitoring.

Clinical trials on the safety and efficacy of Paxlovid in children, people who are pregnant and those with weakened immune systems are ongoing.

™ & © 2023 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.

We want to hear from you.

Have a story idea or tip? Send it to the KSL NewsRadio team here.


BYU nursing student Jane Pearson smiles before donating her bone marrow in late 2023....

Emma Everett Johnson, KSL.COM

BYU student donates bone marrow to potentially save stranger’s life

BYU nursing student Jane Pearson is donating bone marrow to a stranger through the National Marrow Donor Program.

3 hours ago

FILE -- A comfort dog waits for its owner at Salt Lake City International Airport. Experts warn to ...

Britt Johnson

Traveling puts pets at greater risk for canine influenza

Experts warn that now is the time to get pet dogs immunized against canine influenza. 

6 days ago

People present their pets during an animal fashion show....

Mariah Maynes

Here are the health benefits of having pets

According to the USU Extension, interacting with and caring for pets can have positive impacts on your health.

7 days ago


Michelle Lee

Boost your immune system with good nutrition

Let’s Get Moving Host Maria Shilaos spoke with Functional Medicine Nutritionist Karin Reiter to learn how nutrition affects our immune system.

8 days ago

An apple pie surrounded by apples....

Kennedy Camarena

Study shows how processed foods aren’t so great for you

It's always been a pretty well-known fact that processed foods are not that great for people. Now, there's a new study to prove it.

10 days ago

FILE: A two-year-old, plays with dogs outside their home in Ogden on Sunday, Aug. 6, 2023. (Megan N...

Britt Johnson

The spring season leads to increased cases of canine parvovirus

Parvo is especially dangerous for young dogs. It has the potential to wreak havoc on their digestive system.

11 days ago

Sponsored Articles

a doctor putting her hand on the chest of her patient...

Intermountain Health

Intermountain nurse-midwives launch new gynecology access clinic

An access clinic launched by Intermountain nurse-midwives provides women with comprehensive gynecology care.

Young couple hugging while a realtor in a suit hands them keys in a new home...

Utah Association of Realtors

Buying a home this spring? Avoid these 5 costly pitfalls

By avoiding these pitfalls when buying a home this spring, you can ensure your investment will be long-lasting and secure.

a person dressed up as a nordic viking in a dragon boat resembling the bear lake monster...

Bear Lake Convention and Visitors Bureau

The Legend of the Bear Lake Monster

The Bear Lake monster has captivated people in the region for centuries, with tales that range from the believable to the bizarre.


Live Nation Concerts

All the artists coming to Utah First Credit Union Amphitheatre (formerly USANA Amp) this summer

Summer concerts are more than just entertainment; they’re a celebration of life, love, and connection.

Mother and cute toddler child in a little fancy wooden cottage, reading a book, drinking tea and en...

Visit Bear Lake

How to find the best winter lodging in Bear Lake, Utah

Winter lodging in Bear Lake can be more limited than in the summer, but with some careful planning you can easily book your next winter trip.

Happy family in winter clothing at the ski resort, winter time, watching at mountains in front of t...

Visit Bear Lake

Ski more for less: Affordable ski resorts near Bear Lake, Utah

Plan your perfect ski getaway in Bear Lake this winter, with pristine slopes, affordable tickets, and breathtaking scenery.

FDA advisers vote to support Paxlovid for COVID-19 treatment in high-risk adults